NCT00562978View on ClinicalTrials.gov

Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

May 16, 2000

Primary Completion Date

May 21, 2018

Study Completion Date

May 21, 2018

Conditions
Lymphoma
Interventions
BIOLOGICAL

filgrastim

DRUG

cyclophosphamide

DRUG

etoposide

PROCEDURE

AHSCT

RADIATION

yttrium Y 90 ibritumomab tiuxetan

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT00562978 - Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients | Biotech Hunter | Biotech Hunter